Loading company
Xilio Therapeutics, Inc.
XLO · Nasdaq · ·
$9.19+2.2%Sep 29 close
- 1M
- +2.1%
- 6M
- +11.5%
- 1Y
- -22.2%
XLO · Nasdaq · ·
$9.19+2.2%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $18.7M | $8.1M | +131.22% |
| Profit | -$6.4M | -$15.8M | +59.78% |
| Profit per share | -$0.33 | -$2.49 | +86.75% |
| Free Cash Flow | -$18.8M | -$14.9M | -26.23% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Xilio Therapeutics, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Phase 1/2 Clinical Trial XTX501 is an investigational bispecific PD-1 / masked IL-2 designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function while overcoming IL-2 receptor-mediated clearance, peripheral activity and tolerability issues associated with non-masked IL-2 agents. Xilio is evaluating the safety and tolerability of XTX501 as a monotherapy in patients with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors in the Phase 1 portion of a first-in-human, multi-center, open-label Phase 1/2 clinical trial at multiple sites in the United States. Please refer to NCT07688577 on www.clinicaltrials.gov for additional details.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Xilio Therapeutics, Inc.’s Item 2.02 8-K filed August 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.